Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics

The market could potentially see the emergence of new biotech industry leaders. Since the year started, Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT), two clinical-stage drugmakers, have seen their shares skyrocket. The reason? Both companies announced promising clinical progress for their leading pipeline candidates.While there's still some way to go before launching their products, it's hard to argue with the results both Viking and Summit have already achieved. And if they can get that far, they could deliver excellent returns in the long run. But which one looks more attractive?SMMT data by YCharts.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool